Forecasting carbapenem resistance from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit  by Gharbi, M. et al.
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a  b  s  t  r  a  c  t
This study  aimed  to forecast  the incidence  rate  of  carbapenem  resistance  and  to  assess  the  impact
of  an  antimicrobial  stewardship  intervention  using  routine  antimicrobial  consumption  surveillance
data.  Following  an  outbreak  of  OXA-48-producing  Klebsiella  pneumoniae  (January  2008–April  2010)  in
a  renal  cohort  in London,  a  forecasting  ARIMA  model  was  derived  using  meropenem  consumption  data
[deﬁned  daily  dose  per  100  occupied  bed-days  (DDD/100  OBD)]  from  2005–2014  as  a  predictor  of  the
incidence  rate  of  OXA-48-producing  organisms  (number  of  new  cases/year/100,000  OBD).  Interrupted
times  series  assessed  the  impact  of  meropenem  consumption  restriction  as part  of  the  outbreak  con-
trol.  Meropenem  consumption  at lag −1  year  (the  preceding  year),  highly  correlated  with  the  incidence
of  OXA-48-producing  organisms  (r  = 0.71;  P  = 0.005),  was  included  as  a predictor  within  the forecasting
model.  The  number  of  cases/100,000  OBD  for 2014–2015  was  estimated  to  be 4.96 (95% CI  2.53–7.39).
Analysis of  meropenem  consumption  pre-  and post-intervention  demonstrated  an  increase  of  7.12
DDD/100  OBD/year  (95%  CI 2.97–11.27;  P < 0.001)  in  the  4 years  preceding  the  intervention,  but  a  decrease
thereafter.  The  change  in  slope  was −9.11  DDD/100  OBD/year  (95%  CI −13.82  to −4.39). Analysis  of  alter-
native  antimicrobials  showed  a signiﬁcant  increase  in amikacin  consumption  post-intervention  from
0.54  to 3.41  DDD/100  OBD/year  (slope  +0.72,  95% CI 0.29–1.15;  P = 0.01).  Total  antimicrobials  signiﬁ-
cantly  decreased  from  176.21  to  126.24  DDD/100  OBD/year  (P =  0.05).  Surveillance  of  routinely  collected
antimicrobial  consumption  data  may  provide  a  key  warning  indicator  to anticipate  increased  incidence
of  carbapenem-resistant  organisms.  Further  validation  using  real-time  data  is  needed.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Antimicrobial resistance among common bacterial pathogens
s increasing worldwide, with inappropriate and excessive use of
ntimicrobials attributed as a cause [1,2]. Enterobacteriaceae are
mong the most important causes of serious hospital-acquired and
ommunity-onset bacterial infections and have seen a particular
ise in antimicrobial resistance [3,4]. The spread of one resis-
ance mechanism in particular within Enterobacteriaceae, namely
xtended-spectrum -lactamase (ESBL) production, has over the
ast decade contributed to a signiﬁcant increase in carbapenem use
5]. Subsequently, carbapenemase-producing Enterobacteriaceae
∗ Corresponding author. Tel.: +44 20 3313 2732; fax: +44 20 8383 3394.
E-mail addresses: m.gharbi@imperial.ac.uk, m.gharbi@yahoo.fr (M. Gharbi).
ttp://dx.doi.org/10.1016/j.ijantimicag.2015.03.005
924-8579/© 2015 The Authors. Published by Elsevier B.V. This is an open access
y-nc-nd/4.0/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
have appeared and have threatened the efﬁcacy of this antibiotic
class.
Classically, antimicrobial resistance surveillance has been pre-
dominantly retrospective and based upon routinely collected
microbiology data [6], with outbreaks of highly-resistant organ-
isms rarely predicted. Calls for alternative surveillance techniques
have been made, with an early detection system for falling drug
effectiveness key to implementing rapid interventions in order to
prevent the emergence or delay the spread of drug resistance. This
has been advocated at the national level in the UK through the
recent ‘UK 5 year antimicrobial resistance strategy 2013 to 2018
[7] and at the international level through the 2013 G8 summit and
various health organisations reports [3,8,9].
The link between overuse of a particular class of antimicrobials
and selecting possible drug resistance is well established [10].
Therefore, one potential approach to improving surveillance
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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or carbapenem resistance may  be to use routinely collected
ospital antimicrobial consumption data as a predictor for the
otential occurrence of antimicrobial resistance. This approach
as the potential to meet some of the public health objectives of
 surveillance system, namely (i) the detection and/or prediction
f epidemics, (ii) documentation of the spatiotemporal spread of
he disease, (iii) quantitative estimation and characterisation of
he disease burden and (iv) evaluation of control and prevention
nterventions [11].
This study sought to assess the reliability and accuracy of an
utomated and systematic approach to antimicrobial resistance
urveillance using pharmacy-derived antimicrobial consumption
ata. More speciﬁcally, we sought to determine the ability of this
rocess to satisfy two of the main objectives of a surveillance
ystem: (i) prediction of potential outbreaks; and (ii) evaluation
f the impact of antimicrobial stewardship interventions. This is
alidated in the context of the previously described outbreak of
XA-48-producing Klebsiella pneumoniae, the ﬁrst described in the
K, which occurred in the multi-site tertiary referral renal cohort of
 West London teaching hospital between January 2008 and April
010 [12].
. Materials and methods
.1. Data collection and data processing
.1.1. Design and setting
This was a retrospective ecological study of antimicrobial usage
nd resistance conducted in the multi-site (renal medicine, renal
ransplant and haemodialysis satellites) renal cohort of a West
ondon teaching hospital between May  2005 and April 2014.
he teaching hospital has 28 renal inpatient beds and 23 dialy-
is beds and the satellite unit implicated in the outbreak had a
urther 26 dialysis beds, with a total renal patient cohort approx-
mating 3100 dialysis and transplant outpatients. It is the largest
acility in Europe for nephrology, dialysis and transplantation,
reating a large ethnically and demographically diverse popula-
ion.
.1.2. Drug consumption data
Drug consumption data were collected using the hospital phar-
acy system. This system was interrogated for information on
ntimicrobial agents, including antimicrobial name, dose, formu-
ation, route of administration, pack quantity, number of packs
ssued, specialty, ward and hospital site. Renal inpatient and
aemodialysis day-case consumption data were examined at yearly
ime points between May  2005 and April 2014. This captured data
or 4 years before and 5 years after the intervention to contain
he outbreak of OXA-48-producing K. pneumoniae. Antimicro-
ial agents used against Gram-negative infections were analysed.
ntimicrobial consumption in grams was converted into deﬁned
aily doses (DDD) using the 2013 release of the DDD by the
HO  Collaborating Centre for Drug Statistics Methodology [13].
he DDD was adjusted for bed occupancy and presented as DDD
er 100 occupied bed-days per year (DDD/100 OBD/year). For the
urpose of this study, a renal dialysis visit was considered as
 OBD.
.1.3. Microbiology data
Between January 2008 and April 2010, an outbreak of 13 patients
11 clinical cases) with OXA-48-producing K. pneumoniae occurred
n the multi-site renal cohort of a West London teaching hospital;
ohort screening of 1146 patients, contemporaneous to the out-
reak, identiﬁed 2 more cases [12]. This outbreak was limited to
he renal cohort. Subsequent to the outbreak, routine screening was
onducted in the renal unit; four other cases were identiﬁed (threeimicrobial Agents 46 (2015) 150–156 151
clinical cases). Between May  2005 and April 2014, a total of 17 cases
of acquisition of OXA-48-producing K. pneumoniae were identiﬁed
in the renal cohort. The incidence rate (number of new cases per
year per 100,000 OBD) was  plotted over time to describe the trend
in relation to antimicrobial consumption.
In addition to OXA-48-producing K. pneumoniae, two  further
Enterobacteriaceae (Escherichia coli and Citrobacter freundii) encod-
ing this carbapenemase were identiﬁed from the renal cohort [14].
It was not possible to identify whether this represented plasmid
transmission of the resistance element from K. pneumoniae to these
other Enterobacteriaceae within the context of the outbreak; they
were therefore not included in the analysis.
2.1.4. Intervention to contain the outbreak
Epidemiological investigation of the outbreak was  undertaken
to identify potential contributory factors and was previously
described by Thomas et al. [12]. Conclusions derived from that
investigation were that antimicrobial consumption was one of the
main drivers of the OXA-48-producing K. pneumoniae outbreak.
Therefore, the main component of the multilevel intervention
focused on reinforcing antimicrobial stewardship through various
strategies, in addition to immediate infection control measures
(case isolation, screening of contacts, barrier nursing and other
infection control precautions) [12]. A programme to improve
antimicrobial prescribing had been established within the renal
unit to promote a restriction in carbapenem prescribing, which
started sharply in order to contain the outbreak. Local renal antimi-
crobial prescribing policies were reviewed and updated to advocate
use of meropenem only in the presence of aminoglycoside-resistant
micro-organisms.
2.2. Data analysis
2.2.1. Prediction of potential outbreaks
Time series analysis methods were applied to develop a fore-
casting model of the incidence of OXA-48-positive K. pneumoniae
with current or past values (lags) of meropenem consumption used
as explanatory variables.
First, a cross-correlation analysis (Pearson test) at different
time lags between both series of data, namely incidence rate of
OXA-48-positive K. pneumoniae and meropenem consumption, was
performed to identify the point in time where the series are best
aligned. Meropenem consumption with the most associated time
lag to OXA-48-positive K. pneumoniae incidence was  then included
and tested as an external predictor in an autoregressive integrated
moving average (ARIMA) model for multiple time series. Box and
Jenkins approach was  used to identify the parameters of the model
[15,16]. ARIMA models were used as they ﬁt appropriately to time
series data to predict future points in the series, and can include
other time series as predictors. The Portmanteau test (Q test) was
used to identify whether the residuals of the ARIMA model deviated
from white noise.
The accuracy of the univariate model (without external pre-
dictors, i.e. lagged meropenem consumption) and the model of
multiple time series were estimated and compared using the root
mean square error (RMSE) and the coefﬁcient of determination [sta-
tionary R-squared (R2)]. A signiﬁcant decrease of RMSE, which is a
measure of the differences between values predicted by a model
and the values actually observed, using Wilcoxon signed-rank test
denotes an improvement of the model. The R2 characterises the
goodness of ﬁt of a model. Data points ﬁt particularly well a sta-
tistical model when R2 is close to 1. One-step-ahead forecast (year
2014–2015) for OXA-48-positive K. pneumoniae incidence was per-
formed using the model with the best goodness of ﬁt.
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P < 0.001). A signiﬁcant decrease between the predicted values
derivate from the pre-intervention model and the observed values
post-intervention, of −18.99 DDD/100 OBD/year (95% CI −29.66 to
−8.32; P < 0.001) (relative effect = −54.64%), −28.10 (95% CI −41.6852 M. Gharbi et al. / International Journal
.2.2. Evaluation of the impact of the antimicrobial stewardship
ntervention
The impact of the intervention on meropenem consumption was
rst evaluated using a segmented regression analysis of interrupted
ime series (ITS) [17,18]. Data were plotted yearly using ﬁscal years.
his quasi-experimental design was appropriate given the avail-
bility of at least three data points before and three data points
fter the intervention, with a clearly deﬁned intervention period
19]. The analysis enabled estimation of the intervention effect
hilst taking account of time trend and autocorrelation among the
bservations. The ITS allowed an estimation of the change in level
mmediately after the intervention, which is deﬁned as the differ-
nce between the observed level at the ﬁrst intervention time point
nd that predicted by the pre-intervention time trend, the estima-
ion of the difference between pre- and post-intervention slopes,
nd the estimation of yearly average intervention effect after the
ntervention phase [20]. After testing the absence of ﬁrst-order
utocorrelations with the Durbin–Watson statistic, a time series
egression model without adjustment for autocorrelation was ﬁt-
ed to the data of meropenem consumption.
The change in alternative (non-meropenem) antimicrobial con-
umption was analysed post-intervention between 2008–2009 and
013–2014. The change rate and trend (slope) for each antimicro-
ial active against Gram-negative infections were estimated. Total
ntimicrobials included all of the drugs in the therapeutic subgroup
ATC code J01 Antibacterials for systemic use’ from the Anatomical
herapeutic Chemical (ATC) classiﬁcation system [13].
As an indirect control, meropenem consumption in the renal
ohort post-intervention from 2009–2013 was compared with
he overall consumption of meropenem over the same period in
wo other sites of the West London teaching hospital network
who share overarching antimicrobial and infection control poli-
ies; identiﬁed as hospital 1 and hospital 2) previously described
14]. We  also looked at other resistance indicators in the renal
ohort post-intervention, i.e. the proportion of Pseudomonas spp.
isplaying meropenem non-susceptibility and the proportion of
nterobacteriaceae with an ESBL/AmpC phenotype [14].
Statistical analysis was performed using Stata v.12 (StataCorp
P, College Station, TX).
. Results
.1. Forecasting the incidence of OXA-48-producing Klebsiella
neumoniae
The interrelationship among both times series, meropenem
rug consumption and incidence of resistant isolates was identi-
ed using cross-correlations at different time lags (in increments
f 1 year). After ensuring stationarity, absence of residual auto-
orrelation and a normal distribution of disturbances, meropenem
onsumption at lag −1 (i.e. meropenem consumption the preced-
ng year) was the most positively correlated with the incidence
f OXA-48-producing K. pneumoniae (Fig. 1) (Pearson correlation
 = 0.71; P = 0.005). The ARIMA model including meropenem con-
umption at lag −1 as a predictor was ﬁtted to the incidence
f OXA-48-producing K. pneumoniae [meropenem coefﬁcient in
he model = 1.07, 95% conﬁdence interval (CI) 0.10–2.05; P = 0.03].
his increased the model’s accuracy in estimating the incidence
f OXA-48-producing K. pneumoniae compared with the univari-
te ARIMA model without any predictors (RMSE = 1.41 and R2 = 79%
or the multivariate model versus RMSE = 2.92 and R2 = 15% for the
nivariate model). The difference between the two  RMSE were
tatistically different with Wilcoxon signed-rank test (P < 0.001).
ne-step (year)-ahead forecasting for 2014–2015 was then applied
o the incidence rate of resistant cases using the multiple time seriesFig. 1. Cross-correlation between meropenem consumption lag −1 (the preceding
year) and the incidence rate of OXA-48-producing Klebsiella pneumoniae in a West
London renal unit from 2008–2009 to 2013–2014.
model identiﬁed previously. The number of cases/100,000 OBD for
2014–2015 was  estimated to be 4.96 (95% CI 2.53–7.39) (Fig. 2).
3.2. Evaluation of the impact of the antimicrobial stewardship
intervention
The impact of the antimicrobial stewardship intervention fol-
lowing the outbreak of OXA-48-producing K. pneumoniae on
meropenem consumption is depicted in Fig. 3.
Pre-intervention, meropenem consumption showed a year-
on-year increase from 6.30 to 25.65 DDD/100 OBD/year between
2005–2006 and 2008–2009 (slope = +7.12 DDD/100 OBD/year, 95%
CI 2.97–11.27; P < 0.001). After the intervention, meropenem
decreased year-on-year from 25.65 to 10.00 DDD/100 OBD/year
between 2008–2009 and 2013–2014. The difference between the
slope pre- and post-intervention was–9.11 (95% CI −13.82 to −4.39;Fig. 2. Multiple time series analysis for forecasting one-step (year)-ahead inci-
dence rate of OXA-48-producing Klebsiella pneumoniae (cases/100,000 OBD) using
meropenem consumption (in DDD/100 OBD) lag −1 as an external predictor in a
West London renal unit from 2008–2009 to 2013–2014. DDD, deﬁned daily doses;
OBD, occupied bed-days.
M. Gharbi et al. / International Journal of Ant
Fig. 3. Interrupted time series of meropenem consumption (in DDD/100OBD) before
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o −14.51; P < 0.001) (relative effect = −67.09%), −37.20 (95% CI
54.52 to −19.89; P < 0.001) (relative effect = −75.92%), −46.31
95% CI −67.74 to −24.88; P < 0.001) (relative effect = −82.51%)
nd −55.42 (95% CI −81.18 to −29.66; P < 0.001) (relative
ffect = −87.62%) were respectively observed 1, 2, 3, 4 and 5 years
fter the intervention.
Consumption of alternative antimicrobials post-intervention is
escribed Table 1 and Fig. 4. In the post-intervention phase, the
wo alternative Gram-negative antimicrobial classes showed a sig-
iﬁcant increase in consumption from 2008–2009 to 2013–2014;
mikacin increased from 0.54 to 3.41 DDD/100 OBD/year
slope = +0.72, 95% CI 0.29–1.15; P = 0.01) and cephalosporins
rom 0.98 to 1.88 DDD/100 OBD/year (slope = +0.19, 95% CI
.12–0.27; P < 0.01). Use of ertapenem and imipenem demon-
trated a non-signiﬁcant increase over the post-intervention
eriod, although usage of the latter was in general particularly low.
he commonly encountered inhibitor/penicillin combinations, i.e.
moxicillin/clavulanic acid and piperacillin/tazobactam (TZP), did
ot change signiﬁcantly over time (respectively, slope = −0.09,
5% CI −1.31 to 1.12, P = 0.85; and slope = +0.65, 95% CI −0.96 to
.27, P = 0.33). Quinolones signiﬁcantly decreased from 24.82 to
8.57 DDD/100 OBD/year (slope = −1.42, 95% CI −2.05 to −0.78;
 < 0.01). The overall amount of antimicrobials consumed sig-
iﬁcantly decreased from 176.21 to 126.24 DDD/100 OBD/year
slope = −7.21, 95% CI −14.85 to −0.01; P = 0.05).
The data published by Moore et al. [14] and used as an indi-
ect control for the purpose of this study demonstrated that the
ecrease in meropenem consumption (14.2 to 8.5 DDD/100 OBD
rom 2009 to 2013) in the renal unit (excluding haemodialy-
is day-case consumption) was not seen elsewhere. The overall
onsumption of meropenem in hospital 1 and 2 increased,
espectively, from 7.7 to 10.6 DDD/100 OBD and from 3.9 to
.1 DDD/100 OBD. Furthermore, when other resistant organ-
sm prevalence in the renal cohort was analysed, an increase
f ESBL/AmpC-producing Enterobacteriaceae increasing year-on-
ear post-intervention (from 35.6% to 51.5%) but a decrease in
eropenem non-susceptible Pseudomonas spp. (from 32.9% to
8.6%) was observed [14].. Discussion
We  demonstrated that monitoring antimicrobial consumption
s a valid surveillance tool for forecasting potential emergence andimicrobial Agents 46 (2015) 150–156 153
outbreaks of carbapenem-resistant organisms as well as for mon-
itoring the impact of an antimicrobial stewardship intervention.
Such surveillance of hospital antimicrobial consumption, and eval-
uation of antimicrobial stewardship programmes, is considered
to be of key importance in controlling bacterial resistance and
healthcare-associated infections if implemented in real time [7].
This study assessed the reliability of a predictive model using
antimicrobial consumption data as a surveillance system for mon-
itoring antimicrobial resistance. The historical example of an
outbreak of OXA-48-producing K. pneumoniae in a renal cohort in
West London between 2008 and 2010 was used to validate this as
a proof of concept.
We  demonstrated that monitoring antimicrobial consump-
tion can be an accurate tool to forecast potential outbreaks. We
stressed a temporal association between meropenem consump-
tion and OXA-48-producing K. pneumoniae incidence. Moreover,
we developed an ARIMA model using meropenem consumption the
preceding year as an external predictor to forecast the incidence
rate of OXA-48-producing K. pneumoniae; 71% (R2 = 0.71) of the
total variation in OXA-48-producing K. pneumoniae incidence could
be explained by the model. Using this outbreak of carbapenem-
resistant organisms in exemplar, a prediction model can be devised
for future routine surveillance including real-time data.
The results also demonstrated that monitoring antimicrobial
consumption enabled the evaluation of an antimicrobial steward-
ship intervention to contain the outbreak of OXA-48-producing
K. pneumoniae. The results, which derived from ITS analysis, con-
ﬁrmed that the intervention was effective in reducing meropenem
consumption in the renal cohort, consequently reducing the
antimicrobial selective pressure towards carbapenem resistance.
The ITS analysis demonstrated a signiﬁcant increase in meropenem
consumption pre-intervention that may  be explained by some of
the local and specialty drivers of antimicrobial prescribing in the
renal services: (i) fear over increasing prevalence of antimicrobial
resistance to the cephalosporin, ﬂuoroquinolone and aminogly-
coside antimicrobials among E. coli and other Enterobacteriaceae
[4]; (ii) preference for the pharmacokinetic/pharmacodynamic pro-
ﬁle of meropenem over that of TZP for haemodialysis patients
[21,22]; (iii) a disinclination towards use of aminoglycosides owing
to associated toxicity; and (iv) an avoidance for ciproﬂoxacin in
treatment regimens owing to its impact on Clostridium difﬁcile-
associated infections [23,24]. An investigation into the drivers
behind meropenem usage in renal services needs to be undertaken,
including multifactorial motivators that may  include self-reported
prescriber drivers but also contextual organisational and external
factors. The success of the intervention, which was demonstrated
in our analyses by a signiﬁcant decrease in both meropenem usage
and total consumption of antimicrobials post-implementation, was
reached through a common effort of a multidisciplinary antimicro-
bial team, i.e. clinical microbiologists, renal clinicians, pharmacists
and infectious diseases physicians. The impact of the intervention
was still signiﬁcant and sustainable 5 years after deployment of
the ﬁrst measures for containing the outbreak, although a small but
non-signiﬁcant increase in meropenem consumption was observed
in the most recent ﬁscal year analysed. Such longevity of impact
was facilitated both by the amendment of antimicrobial policy to
reﬂect the new practice and by the regular ongoing multidisci-
plinary antimicrobial review rounds, but the need to be mindful
of any decrease in the intensity of the antimicrobial stewardship
intervention is constant.
We also demonstrated that the intervention had an impact on
increasing alternative antimicrobial consumption. Whilst the over-
all antimicrobial consumption and quinolone usage did decrease
signiﬁcantly, a signiﬁcant increase in amikacin and cephalosporin
consumption post-intervention and a small rise in TZP consump-
tion was observed. Use of TZP with amikacin as ﬁrst-line treatment
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Table  1
Impact of a targeted antimicrobial stewardship intervention on antimicrobial drug consumption (DDD/100 OBD) in a West London renal unit from 2008–2009 to 2013–2014.
2008–2009 2009–2010 2010–2011 2011–2012 2012–2013 2013–2014 Change
rate (%)a
Slopeb Standard
error
P-value
Amikacin 0.54 0.67 1.17 1.91 4.06 3.41 526.81 0.72 0.16 0.01
Amoxicillin/clavulanic acid 15.35 12.68 13.77 17.15 14.29 13.08 −14.83 −0.09 0.44 0.85
Cephalosporinsc 0.98 0.99 1.09 1.50 1.62 1.88 91.98 0.19 0.03 <0.01
Ertapenem 1.44 0.99 1.42 0.67 1.85 1.53 6.10 0.06 0.11 0.58
Gentamicin 0.61 0.60 0.22 1.99 0.31 0.60 −2.90 0.02 0.17 0.90
Imipenem 0.03 0.02 0.00 0.00 0.10 0.09 186.66 0.02 0.01 0.16
Meropenem 25.65 16.00 16.68 7.92 8.83 10.00 −61.02 −3.10 0.91 0.03
Piperacillin/tazobactam 8.41 11.45 13.47 15.80 13.30 11.41 35.64 0.65 0.58 0.33
Quinolones 24.82 22.96 22.47 20.45 17.53 18.57 −25.20 −1.42 0.23 <0.01
Totald 176.21 137.49 145.27 143.76 137.14 126.24 −28.36 −7.21 2.76 0.05
DDD, deﬁned daily doses; OBD, occupied bed-days.
a Change rate between 2008–2009 and 2013–2014.
b Trend in antimicrobial consumption from 2008–2009 to 2013–2014.
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rCephalosporins used in renal unit includes cefalexin, cefazolin, cefotaxime, ceft
d Total includes antibacterials for systemic use [Anatomical Therapeutic Chemica
or sepsis was then associated with additional precautions, par-
icularly in the presence of impairment of renal function and
enal replacement therapy. Use of amikacin instead of gentam-
cin could be explained by local epidemiology data, which showed
igh rates of gentamicin resistance in Gram-negative organisms
ut preserved amikacin susceptibility (data not shown), possibly
ttributable to clonal expansion of a speciﬁc aminoglycoside resis-
ance mechanism among Enterobacteriaceae in the local cohorts.
he data reported by Moore et al. [14] suggest that consump-
ion of meropenem in two control groups increased slightly over
he post-intervention period while decreasing in the renal cohort.
hese results emphasise the efﬁcacy of the intervention in reduc-
ng meropenem consumption in the renal cohort. Although the
ates of ESBL/AmpC-producing Enterobacteriaceae in the renal
ohort were noted to increase during the post-implementation
eriod, there was no contemporaneous increase in -lactam or
ephalosporin prescribing to account for this. The variation in
SBL/AmpC-producing Enterobacteriaceae prevalence may  there-
ore reﬂect other driving factors, possibly that of more widespread
lonal expansion of resistant strains [25].
ig. 4. Change rate of the consumption of antimicrobials active against Gram-negative b
enal  cohort. DDD, deﬁned daily doses; OBD, occupied bed-days.e, ceftriaxone and cefuroxime.
) code J01] [13].
In this study, we advocate measurement of hospital antimi-
crobial consumption at the cohort-speciﬁc level as a monitoring
and prediction tool to inform antimicrobial resistance surveil-
lance. However, this approach presents some limitations. First,
this system would be more robust using patient-level antimicro-
bial prescribing data supported by recording of clinical indications
and linked to patient-level microbiology data. Furthermore, whilst
the electronic and accurate nature of this data set enables ease of
extraction and facilitates a move towards the goal of automated
real-time analyses, the yearly aggregated data available for this
study have the potential to limit the accuracy of the estimated
forecast values. As an interim, a monthly surveillance system is
being validated and will be used for future prospective surveil-
lance. A further limitation of this study reﬂects uncertainty over
the optimal metric to quantify antimicrobial consumption. Use of
DDD/100 OBD is not an optimal measure, especially among renal
impairment patients or paediatric populations as it is weight- and
dosage-independent [26]. Recent evidence suggests ‘days of ther-
apy’ as an index could present advantages over DDD measures by
limiting the impact of dosage variability among patients [26,27].
acteria (in DDD/100 OBD) between 2008–2009 and 2013–2014 in a West London
 of Ant
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nly an electronic-based system recording patients’ medication
dministration data would enable routine use of this indicator to
ssess stewardship efforts. The usage of ‘days of presence’ instead
f occupied bed-days as a denominator would be more speciﬁc in
aking into account every location that patients occupied for any
ime on a given day, but again it requires electronic prescribing
27]. Finally, as the intervention had been implemented rapidly
n response to a speciﬁc outbreak, no contemporaneous control
roup was available for the analysis. The ITS analysis was  chosen
or this reason, using the pre-intervention period as a control for
he post-intervention period.
This study suggests that a surveillance system using antimicro-
ial consumption data may  be able to be used as an early warning
ystem to predict the potential emergence of resistant organisms, if
 prospective validation was performed and the timeframe of data
ollection became monthly [28]. Monitoring antimicrobial con-
umption can also provide guidance on antimicrobial stewardship
rogrammes and assess their impact within the hospital.
In conclusion, antimicrobial consumption data provide a key
ool not only for the evaluation of antimicrobial stewardship inter-
entions, but also for forecasting emergence and future potential
utbreaks and trends in the prevalence of antimicrobial resistance.
onitoring antimicrobial consumption data should be considered
n real time as an early warning system devised as part of healthcare
rganisations’ antimicrobial stewardship programmes. Using this
ethod, local practices can be compared nationally or internation-
lly to aid control of unnecessary antimicrobial exposure. Various
fforts have already started worldwide to control transmission
f carbapenem resistance among Enterobacteriaceae [3,7,29,30].
 local real-time surveillance system for monitoring antimicro-
ial consumption across acute-care settings would complement
ational and international toolkits developed for containing the
pread of resistance.
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